Physician profile
Amy J Cleemput
NPI 1568702678
$3,336.56
in general payments reported to CMS, 2019-2025
21 companies · $2,241 in 2025
The $2,241 reported for 2025 was more than what 93% of Adult Health (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $186).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.56 · 2024: $1,084 · 2025: $2,241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,952 · Education: $373.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,951.79 |
| Education | $373.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $483.16 | 2024-2025 | Tremfya, Simponi Aria, Simponi |
| Abbvie INC. | $451.71 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $412.86 | 2024-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $301.29 | 2024-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $238.92 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $224.87 | 2024-2025 | |
| Lilly USA, LLC | $202.06 | 2024-2025 | Ebglyss, Taltz, Olumiant |
| Incyte Corporation | $192.39 | 2024-2025 | Opzelura |
| Ucb, INC. | $180.31 | 2024-2025 | Bimzelx |
| Amgen INC. | $166.29 | 2024-2025 | Otezla, Otezla |
| Sanofi-Aventis U.S. LLC | $94.99 | 2024 | |
| Leo Pharma INC. | $82.03 | 2024-2025 | Adbry |
| Genentech USA, INC. | $76.79 | 2024-2025 | Xolair, Erivedge |
| Sun Pharmaceutical Industries INC. | $48.50 | 2024-2025 | |
| Verrica Pharmaceuticals INC. | $44.42 | 2024-2025 | Ycanth |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $40.62 | 2025 | Nemluvio |
| Organon LLC | $25.26 | 2025 | |
| Organogenesis INC. | $20.88 | 2025 | Affinity |
| Pfizer INC. | $19.02 | 2025 | |
| Arcutis Biotherapeutics, INC. | $18.63 | 2025 | Zoryve |
| Astrazeneca Pharmaceuticals Lp | $11.56 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Cleemput listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.